{
    "title": "CardioTox: The Oncora Scandal",
    "industry": "Pharmaceuticals",
    "ground_truth_dossier": {
        "FACT_001": "Oncora Therapeutics' experimental cancer drug ONC-47 showed a 3.2% increase in heart failure events during Phase III trials, disclosed in the trial summary submitted to the FDA.",
        "FACT_002": "Internal cardiology safety board flagged a 12.7% heart failure rate in patients over 65\u2014four times higher than the published 3.2% overall rate\u2014but this age-stratified data was excluded from the public trial summary.",
        "FACT_003": "Chief Medical Officer Dr. Helena Voss sent an email to the CEO recommending a 6-month trial pause to investigate cardiac signals, but was overruled with the instruction to 'manage the optics, not the timeline.'",
        "FACT_004": "A data analyst discovered that 8 patient deaths originally classified as 'disease progression' showed autopsy evidence of acute heart failure, but these cases were never reclassified in safety databases.",
        "FACT_005": "Oncora's contract research organization (CRO) used a non-standard cardiac monitoring protocol that measured heart function every 90 days instead of the FDA-recommended 30 days, potentially missing early warning signs.",
        "FACT_006": "The company's lead investor, Apex Capital, pressured executives in a board meeting to accelerate FDA submission before Q4 earnings, stating 'cardiac noise is manageable if we control the narrative.'",
        "FACT_007": "An ongoing parallel trial in Europe was quietly halted by German regulators after 2 sudden cardiac deaths, but Oncora did not disclose this suspension in their U.S. FDA application."
    },
    "initial_state": {
        "public_fact_ids": [
            "FACT_001"
        ],
        "private_fact_ids": [
            "FACT_002",
            "FACT_003",
            "FACT_005"
        ],
        "public_narrative": "BREAKING: Patient dies of heart failure during trial of Oncora's promising cancer drug ONC-47. Family attorney alleges 'inadequate safety monitoring.' Oncora stock down 18% in pre-market trading.",
        "private_narrative": "URGENT - INTERNAL BRIEFING: A 68-year-old trial participant (Site 34, Boston) died of acute heart failure. Family has retained legal counsel. Public trial data shows 3.2% cardiac events, but internal stratified analysis shows 12.7% in over-65 cohort. CMO's pause recommendation was overruled last quarter. FDA submission is in 6 weeks. Legal and Comms teams need unified messaging. CEO wants statement ready in 2 hours."
    },
    "event_pool": [
        {
            "id": "EVENT_001",
            "type": "EXTERNAL_REACTION",
            "target_fact_id": "N/A",
            "text": "Cardiology Today publishes editorial: 'The ONC-47 Case: Why Age-Stratified Safety Data Should Be Mandatory.' Three prominent oncologists call for greater transparency in cancer drug trials on Twitter.",
            "condition": "Trigger 24-48 hours after initial crisis if company issues a generic statement without addressing age-specific concerns or detailed safety data."
        },
        {
            "id": "EVENT_002",
            "type": "INFORMATION_LEAK",
            "target_fact_id": "FACT_002",
            "text": "ProPublica publishes leaked internal safety memo showing 12.7% heart failure rate in patients over 65\u2014four times the publicly disclosed overall rate. Headline: 'Cancer Drug Maker Hid Cardiac Risks for Elderly Patients.'",
            "condition": "Trigger if company denies any knowledge of elevated risks beyond the 3.2% figure, or if public pressure for data transparency intensifies without adequate company response within 72 hours."
        },
        {
            "id": "EVENT_003",
            "type": "INTERNAL_DISCOVERY",
            "target_fact_id": "FACT_004",
            "text": "Risk management team conducts urgent internal audit and discovers 8 deaths originally coded as 'disease progression' have autopsy reports showing acute heart failure as cause of death. Legal warns this could constitute misclassification.",
            "condition": "Trigger if company commits to an internal review of safety protocols or if external pressure demands re-examination of trial death classifications."
        },
        {
            "id": "EVENT_004",
            "type": "EXTERNAL_REACTION",
            "target_fact_id": "N/A",
            "text": "Sen. Elizabeth Warren sends letter to FDA demanding investigation into Oncora's trial safety practices. Letter is posted publicly on Senate.gov and widely shared. #OncoraCoverUp trends on Twitter.",
            "condition": "Trigger if leaked information (FACT_002 or similar) becomes public, or if company statements are perceived as evasive or misleading by patient advocacy groups."
        },
        {
            "id": "EVENT_005",
            "type": "INFORMATION_LEAK",
            "target_fact_id": "FACT_003",
            "text": "Anonymous whistleblower provides The Wall Street Journal with internal emails showing CMO recommended trial pause to investigate cardiac events, but was overruled by CEO with directive to 'manage the optics, not the timeline.'",
            "condition": "Trigger if company publicly claims it acted on all safety recommendations, or if internal employees feel leadership is scapegoating medical staff. More likely after 5-7 days of sustained crisis."
        },
        {
            "id": "EVENT_006",
            "type": "EXTERNAL_REACTION",
            "target_fact_id": "N/A",
            "text": "Patient advocacy group 'Cancer Patients United' stages protest outside Oncora headquarters with signs reading 'Profits Over Hearts' and 'Our Parents Aren't Expendable.' Local news covers extensively.",
            "condition": "Trigger if age-stratified risk data (FACT_002) becomes public, or if company communications are perceived as dismissive of elderly patient safety."
        },
        {
            "id": "EVENT_007",
            "type": "INTERNAL_DISCOVERY",
            "target_fact_id": "FACT_006",
            "text": "General Counsel reviews board meeting minutes and finds documented pressure from lead investor Apex Capital to accelerate FDA timeline despite safety signals, including quote: 'cardiac noise is manageable if we control the narrative.'",
            "condition": "Trigger if internal investigation is launched, or if company attempts to claim decisions were purely medical/scientific without investor pressure. More likely if executive leadership faces scrutiny."
        },
        {
            "id": "EVENT_008",
            "type": "EXTERNAL_REACTION",
            "target_fact_id": "N/A",
            "text": "Class action lawsuit filed by families of 14 trial participants who experienced cardiac events. Lead attorney announces lawsuit at press conference, stating 'Oncora chose shareholder value over patient lives.'",
            "condition": "Trigger if multiple damaging facts become public, or if company denies wrongdoing despite evidence suggesting negligence. Typically occurs 4-7 days into crisis."
        },
        {
            "id": "EVENT_009",
            "type": "INFORMATION_LEAK",
            "target_fact_id": "FACT_005",
            "text": "Reuters investigation reveals Oncora used 90-day cardiac monitoring intervals instead of FDA-recommended 30-day intervals. Former CRO employee states: 'We raised concerns but were told the protocol was final.'",
            "condition": "Trigger if journalists begin investigating trial methodology, or if company claims it followed all standard safety monitoring protocols without caveat."
        },
        {
            "id": "EVENT_010",
            "type": "INTERNAL_DISCOVERY",
            "target_fact_id": "FACT_007",
            "text": "Regulatory affairs team discovers that the parallel European trial was suspended by German BfArM after 2 sudden cardiac deaths\u2014and this suspension was never disclosed in the U.S. FDA application. Legal assesses this as potential regulatory fraud.",
            "condition": "Trigger if FDA announces its own investigation, or if company conducts comprehensive internal audit of all global trial activities and regulatory submissions."
        },
        {
            "id": "EVENT_011",
            "type": "EXTERNAL_REACTION",
            "target_fact_id": "N/A",
            "text": "FDA issues public statement: 'We are aware of serious concerns regarding ONC-47 trial conduct and are launching a full investigation into safety reporting practices.' Oncora stock drops additional 31%.",
            "condition": "Trigger if multiple safety concerns become public (2+ leaked facts), or if external pressure from lawmakers and media reaches critical threshold within 5-7 days."
        },
        {
            "id": "EVENT_012",
            "type": "INFORMATION_LEAK",
            "target_fact_id": "FACT_004",
            "text": "Bloomberg obtains internal audit showing 8 trial deaths were misclassified. Headline: 'Oncora Coded Heart Failure Deaths as Cancer Progression, Internal Docs Show.' Forensic pathologist calls it 'systematic misattribution.'",
            "condition": "Trigger if company announces internal audit findings publicly but attempts to minimize scope, or if whistleblower/hacker accesses audit documents. More likely 7-10 days into crisis."
        },
        {
            "id": "EVENT_013",
            "type": "EXTERNAL_REACTION",
            "target_fact_id": "N/A",
            "text": "American Heart Association releases statement expressing 'grave concern' about trial practices and calling for independent review of all ONC-47 cardiac safety data. Statement is cited in 200+ news articles within 12 hours.",
            "condition": "Trigger if cardiac monitoring deficiencies (FACT_005) become public, or if medical community perceives pattern of safety protocol violations."
        },
        {
            "id": "EVENT_014",
            "type": "INFORMATION_LEAK",
            "target_fact_id": "FACT_006",
            "text": "Hacker collective releases full board meeting transcripts showing investor pressure to 'control the narrative' on cardiac safety. Apex Capital partner's statement: 'We need the FDA approval before Q4\u2014manage the cardiac noise' goes viral.",
            "condition": "Trigger if company blames 'rogue employees' or claims executive decisions were made in good faith, or if sustained crisis reaches 10-14 days with multiple prior leaks creating whistleblower momentum."
        },
        {
            "id": "EVENT_015",
            "type": "INFORMATION_LEAK",
            "target_fact_id": "FACT_007",
            "text": "Financial Times obtains German regulatory documents showing European trial suspension after cardiac deaths\u2014never disclosed to FDA. FDA Commissioner tweets: 'If true, this represents serious regulatory breach.' Criminal investigation mentioned by DOJ sources.",
            "condition": "Trigger if FDA investigation intensifies, or if international journalists coordinate with U.S. media on cross-border investigation. Most likely 10-15 days into crisis as investigators expand scope globally."
        }
    ]
}